Implanted Microdevice Tests Drugs Inside Tumors in People With Sarcoma
Tests a small implanted device that releases drugs into sarcoma tumors in patients.
Plain-language title generated from the registry record
Registry title: Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
Key facts
- Where
- Houston, United StatesSee the site
Where in United States
- M D Anderson Cancer CenterHouston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- M.D. Anderson Cancer Center
- Trial code
- NCT04199026
- Record updated
- 11 August 2026
- Original description
This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue and are loaded with 10 different drugs that are delivered at very small doses, or "microdoses," which may only affect a very small, local area inside the tumor. The purpose of this study is to determine which drugs delivered in the microdevice affect tumor tissue in patients with sarcomas.Read full original descriptionShow less
Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Sarcomas
This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue and are loaded with 10 different drugs that are delivered at very small doses, or "microdoses," which may only affect a very small, local area inside the tumor. The purpose of this study is to determine which drugs delivered in the microdevice affect tumor tissue in patients with sarcomas.
Inclusion:; Patients with a biopsy-confirmed recurrent or metastatic sarcoma for which surgery is indicated as a standard of care; 10 years of age or older; Documented, signed, dated informed consent to participate in the microdevice study; Eastern Cooperative Oncology Group (ECOG) performance status of =< 2; Exclusion:; Subjects who do not wish to undergo surgical resection, or those who are high-risk or not candidates for surgical resection; Age < 10 years old; Women of childbearing potential without a negative pregnancy test; or women who are lactating; Allergies or prior adverse drug reactions to any of the drugs loaded within the microdevice.